AbbVie

NEWS: We’ve entered into a global license agreement with FutureGen to develop a next generation monoclonal #antibody for the treatment of #IBD. Learn more: https://bit.ly/3Xlau18 [Video description: On-screen text reads, “Immunology News.”]

How do we support our employees' well-being journeys? Through programs like AbbVie in Motion that encourage them to be active, build #HealthyHabits, connect as a team and have fun. Hear employees around the world share how being active supports their overall well-being. Explore our programs: https://bit.ly/3xhfrxw  [Video description: AbbVie employees answer the on-screen prompt, “How does being active support your overall well-being?”]

Having a diverse workforce and an inclusive working environment is a business necessity, which is why we’re proud to again be named one of Seramount's Best Companies for Multicultural Women. Learn more: https://bit.ly/4c34HSI #SeramountMCW #BelongAtAbbVie

At #EULAR2024, we’re presenting 25 abstracts showcasing data across our #rheumatology portfolio. Learn more about our commitment to delivering solutions for people with immune-mediated diseases: https://bit.ly/3Xl1LMG [Video description: Sofie Berg, Pharm.D, Ph.D., Therapeutic Area Head, International Immunology, International Medical Affairs, AbbVie, says, “With our rich legacy and understanding of rheumatic diseases, I’m encouraged by the growing body of evidence and long-term data our teams are presenting at EULAR this year as we continue our efforts to advance research in this space.”]

The 4-year follow up results of the randomized Phase 3 GAIA/CLL13 study in #patients with chronic lymphocytic leukemia (#CLL), comparing different first line time-limited therapies, was recently published in The Lancet. Read more: https://bit.ly/3x3aZCz

Through insights from the AbbVie Research Collaborative, our #scientists are gaining a deeper understanding of individual patient needs. That’s why Patrick Lank and his team are making big bets in #technology and #science to accelerate the discovery and development of medicines. See how we’re building the lab of the future: https://bit.ly/45fgURz [Video description: Patrick Lank, medical director, AbbVie, shares an introduction to the AbbVie Research Collaborative. On-screen text reads, “Click the link to see how we’re making the case for big bets. People. Passion. Possibilities.”]

ICYMI: The first patient has been dosed in the Phase 3 study evaluating our investigational therapy in patients with relapsed/refractory #MultipleMyeloma. Read more: https://bit.ly/3Vhp6fx [Video description: On-screen text reads, “Oncology News.”]

Today, we announced topline results from the Phase 2 trial evaluating an investigational antibody-drug conjugate (#ADC) in heavily pre-treated patients with folate receptor-alpha positive, platinum-sensitive #OvarianCancer (PSOC). Learn more: https://bit.ly/3RhbwYa [Video description: On-screen text reads, “Oncology News.”]

Our medicines can be a source of hope for patients. That’s why our #MarketAccess teams work every day to ensure the patients who need them can access them. Explore our #career opportunities to help make a remarkable impact: https://bit.ly/4aTAL9T

Creating tomorrow’s cures requires investing in today’s #entrepreneurs. That’s why AbbVie Ventures was established 15 years ago and has been investing in novel, transformational #therapeutics at discovery and preclinical stages ever since. Learn more in the 2023 Year-In-Review: https://lnkd.in/gKc5yctT [Image description: Two scientists talking while working in lab. On-screen text reads, "Investing to Develop Tomorrow’s Cures by Today’s Entrepreneurs. 2023 Year-In-Review."]